AMAG Pharmaceuticals (AMAG) Rating Reiterated by B. Riley

AMAG Pharmaceuticals (NASDAQ:AMAG)‘s stock had its “buy” rating reiterated by stock analysts at B. Riley in a note issued to investors on Friday, MarketBeat reports. They currently have a $20.50 price objective on the specialty pharmaceutical company’s stock, down from their previous price objective of $29.00. B. Riley’s target price indicates a potential upside of 22.02% from the stock’s current price.

AMAG has been the subject of a number of other research reports. Deutsche Bank set a $23.00 target price on AMAG Pharmaceuticals and gave the stock a “hold” rating in a report on Thursday, September 20th. Zacks Investment Research downgraded AMAG Pharmaceuticals from a “hold” rating to a “strong sell” rating in a report on Friday, October 5th. Cantor Fitzgerald set a $18.00 price target on AMAG Pharmaceuticals and gave the company a “hold” rating in a research report on Wednesday, September 26th. BidaskClub upgraded AMAG Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Wednesday, October 17th. Finally, ValuEngine cut AMAG Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Friday, September 14th. Three analysts have rated the stock with a sell rating, seven have issued a hold rating, two have given a buy rating and one has assigned a strong buy rating to the company’s stock. AMAG Pharmaceuticals presently has an average rating of “Hold” and an average price target of $20.92.

AMAG Pharmaceuticals stock opened at $16.80 on Friday. The company has a quick ratio of 2.72, a current ratio of 2.86 and a debt-to-equity ratio of 0.34. AMAG Pharmaceuticals has a 52 week low of $11.95 and a 52 week high of $26.10.

AMAG Pharmaceuticals (NASDAQ:AMAG) last released its earnings results on Thursday, November 1st. The specialty pharmaceutical company reported ($1.88) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.77) by ($1.11). AMAG Pharmaceuticals had a negative return on equity of 13.65% and a negative net margin of 6.98%. The firm had revenue of $122.20 million for the quarter, compared to analyst estimates of $118.23 million. During the same period last year, the firm earned ($4.31) EPS. The company’s revenue for the quarter was down 1.7% compared to the same quarter last year. On average, equities research analysts expect that AMAG Pharmaceuticals will post -2.85 EPS for the current fiscal year.

Several institutional investors have recently bought and sold shares of AMAG. Alps Advisors Inc. increased its position in shares of AMAG Pharmaceuticals by 17.6% in the second quarter. Alps Advisors Inc. now owns 53,767 shares of the specialty pharmaceutical company’s stock valued at $712,000 after buying an additional 8,047 shares in the last quarter. First Trust Advisors LP increased its position in shares of AMAG Pharmaceuticals by 106.8% during the second quarter. First Trust Advisors LP now owns 70,869 shares of the specialty pharmaceutical company’s stock worth $1,382,000 after purchasing an additional 36,607 shares in the last quarter. State of Wisconsin Investment Board increased its position in shares of AMAG Pharmaceuticals by 34.6% during the second quarter. State of Wisconsin Investment Board now owns 35,000 shares of the specialty pharmaceutical company’s stock worth $682,000 after purchasing an additional 9,000 shares in the last quarter. Sei Investments Co. increased its position in shares of AMAG Pharmaceuticals by 1,695.3% during the second quarter. Sei Investments Co. now owns 506,429 shares of the specialty pharmaceutical company’s stock worth $9,876,000 after purchasing an additional 478,220 shares in the last quarter. Finally, Canada Pension Plan Investment Board increased its position in shares of AMAG Pharmaceuticals by 15,100.0% during the second quarter. Canada Pension Plan Investment Board now owns 60,800 shares of the specialty pharmaceutical company’s stock worth $1,186,000 after purchasing an additional 60,400 shares in the last quarter.

AMAG Pharmaceuticals Company Profile

AMAG Pharmaceuticals, Inc is a biopharmaceutical company, which focuses on the research, development, and commercialization of a therapeutic iron compound to treat iron deficiency anemia. The firm focuses on the development and commercialization of Feraheme injection for intravenous use to treat iron deficiency anemia.

Featured Article: Why do company’s buyback their stock?

Analyst Recommendations for AMAG Pharmaceuticals (NASDAQ:AMAG)

Receive News & Ratings for AMAG Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AMAG Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.


Leave a Reply